Taiwan · Delayed Price · Currency is TWD Bora Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a sequential revenue decline due to scheduled maintenance and generics headwinds, but March rebounded and strong order backlog supports a positive outlook. Two major acquisitions—MacroGenics CDMO and Weider Global Nutrition—are set to drive growth and diversify revenue.
-
FY2025 saw record revenues, major CDMO contract wins, and expansion into biologics, with specialty pharma now 45% of sales. Investments in U.S. and Taiwan facilities, AI, and ESG initiatives position the company for strong growth in CDMO, biologics, and rare disease markets in 2026.
-
Significant expansion and operational improvements drove 2025 revenue to $634 million, with a 700% market cap increase since 2017. Strategic U.S. investments, a focus on high-value generics and rare diseases, and strong ESG performance position the company for continued growth.
Fiscal Year 2025
-
Record CDMO and specialty pharma growth drove a 15% year-over-year revenue increase and improved margins, despite ongoing integration and external headwinds. Strategic acquisitions, capacity expansions, and a focus on high-value products position the business for continued growth into 2026.
-
Q2 2025 saw 9% sequential and 28% year-over-year revenue growth, with margin recovery expected in H2 as operational delays resolve. CDMO and specialty pharma segments drove strong performance, while proactive tariff and FX management minimized risks.
-
Q1 2025 saw record CDMO growth and a strategic shift to high-margin products, despite lower total revenue due to discontinued low-margin lines and the Clinton facility closure. Gross margin rose to 42%, and specialty pharma sales surged, with strong outlook for CDMO expansion.
-
Achieved rapid revenue and profit growth, expanded global manufacturing, and executed major acquisitions in North America. Focused on integrating new assets, launching innovative CNS products, and investing in capacity, technology, and M&A for continued growth.
Fiscal Year 2024
-
Revenues grew 35.5% and net income rose 31.5% year-over-year, driven by strong CDMO and commercial performance, strategic U.S. acquisitions, and a focus on high-margin products. 2025 outlook is positive with new capacity, product launches, and continued margin improvement.